See also this year's filing and all EDGAR filings for this company.
PDF Report 0001606645_2018_Foamix_Pharmaceuticals_Ltd.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.11812667575051645, 'aggregate_val': 80254000, 'exp_sum': 91004000, 'exp_to_value': {'AssetsCurrent': 69504000, 'AssetsNoncurrent': 10750000, 'PropertyPlantAndEquipmentNet': 2042000, 'Goodwill': 0, 'remainder_Assets': 8708000}} |
| info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('EntityCommonStockSharesOutstanding')"} |
Graph
Absolute values for 0001606645, Foamix Pharmaceuticals Ltd.
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 1,425,000 |
| 1 | LiabilitiesCurrent | 10,228,000 |
| 2 | remainder_Liabilities | 0 |
| 3 | AssetsCurrent | 69,504,000 |
| 4 | AssetsNoncurrent | 10,750,000 |
| 5 | PropertyPlantAndEquipmentNet | 2,042,000 |
| 6 | Goodwill | 0 |
| 7 | remainder_Assets | -2,042,000 |
| 8 | GeneralAndAdministrativeExpense | 11,504,000 |
| 9 | ResearchAndDevelopmentExpense | 57,779,000 |
| 10 | remainder_Expenses | 1,164,000 |
| 11 | remainder_Revenues | 3,669,000 |
| 12 | remainder_NetIncome | 1,063,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 11,653,000 |
| 1 | Assets | 80,254,000 |
| 2 | Expenses | 70,447,000 |
| 3 | Revenues | 3,669,000 |
| 4 | StockholdersEquity | 68,601,000 |
| 5 | NetIncome | -65,715,000 |
| 6 | ComprehensiveNetIncome | -65,715,000 |
| 7 | BaseVar | 83,543,000 |
| 8 | EconomicCapitalRatio | -0.161 |
Edgar->Model Mapping
Feature Distribution
Change over Time
